SYK
Stryker Corporation · Healthcare · Medical - Devices
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 172 | +2 | 222.53M | $70.41B | +7 | −4 |
| Q1 2026 | 172 | -2 | 215.42M | $70.87B | +1 | −4 |
| Q4 2025 | 173 | -1 | 229.53M | $80.67B | +1 | −1 |
| Q3 2025 | 25 | +3 | 142.80M | $52.79B | +4 | −2 |
| Q2 2025 | 20 | 0 | 117.11M | $46.33B | +1 | −1 |
| Q1 2025 | 17 | -2 | 51.08M | $19.01B | — | −2 |
| Q4 2024 | 19 | 0 | 52.07M | $18.75B | +1 | −1 |
| Q3 2024 | 18 | +2 | 39.19M | $14.15B | +2 | — |
| Q2 2024 | 16 | — | 41.27M | $14.03B | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 11.70M | — | $3.98B | 0.5% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 11.70M | — | $3.98B | 0.5% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 11.24M | — | $3.82B | 0.7% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 6.74M | — | $2.29B | 0.2% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passief) | 6.74M | — | $2.29B | 0.2% | n/c | 1 | SEC ↗ |
| 13 | Norges Bank ✦ (passief) | 5.00M | — | $1.70B | 0.3% | n/c | 1 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 4.28M | — | $1.46B | 0.6% | n/c | 1 | SEC ↗ |
| 15 | PRIMECAP Management ✦ | 447.50K | — | $152.26M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 375.30K | — | $127.70M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | Adage Capital Partners ✦ | 325.20K | — | $110.65M | 0.2% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 324.94K | — | $110.56M | 0.2% | n/c | 1 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 324.94K | — | $110.56M | 0.2% | n/c | 1 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 306.80K | — | $104.39M | 0.5% | n/c | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 232.64K | — | $79.16M | 0.2% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 125.33K | — | $42.49M | 0.1% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 125.33K | — | $42.49M | 0.1% | n/c | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 125.33K | — | $42.49M | 0.1% | n/c | 1 | SEC ↗ |
| 25 | Marshall Wace ✦ | 122.20K | — | $41.58M | 0.1% | n/c | 1 | SEC ↗ |
| 26 | Marshall Wace ✦ | 122.20K | — | $41.58M | 0.1% | n/c | 1 | SEC ↗ |
| 27 | Millennium Management ✦ | 33.32K | — | $11.34M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | GAMCO Investors ✦ | 14.19K | — | $4.83M | 0.1% | n/c | 1 | SEC ↗ |
| 29 | Gotham Asset Management ✦ | 1.25K | — | $424,632 | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 2,274 houders, 283.44M aandelen, $87.41B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 805 aand · $276,495
Director · 80 aand · $26,804
Director · 320 aand · $107,774
Director · 2.31K aand · $780,062
Director · 11.26K aand · $3.81M
Director · 10.81K aand · $3.67M
Director · 16.61K aand · $5.66M
Director · 3.27K aand · $1.12M
Director · 3.85K aand · $1.32M
Director · 40 aand · $13,272
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie